Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 270

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Polypill with or without Aspirin in Persons without Cardiovascular Disease

Open access
Yusuf, Salim, Joseph, Philip, Dans, Antonio, Gao, Peggy, Teo, Koon, Xavier, Denis, López-Jaramillo, Patricio, Yusoff, Khalid, Santoso, Anwar, Gamra, Habib, Talukder, Shamim, Christou, Courtney, Girish, Preeti, Yeates, Karen, Xavier, Freeda, Dagenais, Gilles, Rocha, Catalina, McCready, Tara, Tyrwhitt, Jessica, Bosch, Jackie, Pais, Prem·2021·New England Journal of Medicine

Abstract

BACKGROUND: A polypill comprising statins, multiple blood-pressure-lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease. METHODS: Using a 2-by-2-by-2 factorial design, we randomly assigned participants without cardiovascular disease who had an elevated INTERHEART Risk Score to receive a polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily, aspirin (75 mg) or placebo daily, and vitamin D or placebo monthly. We report here the outcomes for the polypill alone as compared with matching placebo, for aspirin alone as compared with matching placebo, and for the polypill plus aspirin as compared with double placebo. For the polypill-alone and polypill-plus-aspirin comparisons, the primary outcome was death from cardiovascular causes, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or revascularization. For the aspirin comparison, the primary outcome was death from cardiovascular causes, myocardial infarction, or stroke. Safety was also assessed. RESULTS: A total of 5713 participants underwent randomization, and the mean follow-up was 4.6 years. The low-density lipoprotein cholesterol level was lower by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 mm Hg with the polypill and with combination therapy than with placebo. The primary outcome for the polypill comparison occurred in 126 participants (4.4%) in the polypill group and in 157 (5.5%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.63 to 1.00). The primary outcome for the aspirin comparison occurred in 116 participants (4.1%) in the aspirin group and in 134 (4.7%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.67 to 1.10). The primary outcome for the polypill-plus-aspirin comparison occurred in 59 participants (4.1%) in the combined-treatment group and in 83 (5.8%) in the double-placebo group (hazard ratio, 0.69; 95% CI, 0.50 to 0.97). The incidence of hypotension or dizziness was higher in groups that received the polypill than in their respective placebo groups. CONCLUSIONS: Combined treatment with a polypill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participants without cardiovascular disease who were at intermediate cardiovascular risk. (Funded by the Wellcome Trust and others; TIPS-3 ClinicalTrials.gov number, NCT01646437.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2028220

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 270

Metadata

Authors
Yusuf, S., Joseph, P., Dans, A., Gao, P., Teo, K., Xavier, D., López-Jaramillo, P., Yusoff, K., Santoso, A., Gamra, H., Talukder, S., Christou, C., Girish, P., Yeates, K., Xavier, F., Dagenais, G., Rocha, C., McCready, T., Tyrwhitt, J., Bosch, J., & Pais, P.
Venue
New England Journal of Medicine
Published
2021-01-21
Volume
384
Issue
3
Pages
216-228
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3101533148
Cited by
270
References
29
FWCI
34.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polypill with or without Aspirin in Persons without Cardiovascular Disease. https://app.cochat.ai/papers/10.1056/nejmoa2028220
The paper
Yusuf, S., Joseph, P., Dans, A., Gao, P., Teo, K., Xavier, D., López-Jaramillo, P., Yusoff, K., Santoso, A., Gamra, H., Talukder, S., Christou, C., Girish, P., Yeates, K., Xavier, F., Dagenais, G., Rocha, C., McCready, T., Tyrwhitt, J., . . . Pais, P. (2021). Polypill with or without Aspirin in Persons without Cardiovascular Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2028220

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.